Keros Therapeutics (KROS) Stock Price, News & Analysis

Company Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $15.25 to $15.56
• 50-Day Range: $13.33 to $15.56
• 52-Week Range: $9.12 to $72.37
• Volume: 130,485 shs
• Average Volume: 963,655 shs
• Market Capitalization: $619.46 million
• P/E Ratio: 49.15
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Moderate Buy

Keros Therapeutics Stock Analysis - MarketRank™

Keros Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 440th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Keros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Keros Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.74) to ($4.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Keros Therapeutics is 49.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Keros Therapeutics is 49.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.76.

Price to Earnings Growth Ratio

Keros Therapeutics has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Keros Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.01% of the float of Keros Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Keros Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Keros Therapeutics has recently decreased by 4.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Keros Therapeutics does not currently pay a dividend.

Dividend Growth

Keros Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.01% of the float of Keros Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Keros Therapeutics has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in Keros Therapeutics has recently decreased by 4.16%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.13

News Sentiment

Keros Therapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Keros Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for KROS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KROS Stock Analysis - Frequently Asked Questions

How have KROS shares performed this year?

Keros Therapeutics' stock was trading at $15.83 at the beginning of 2025. Since then, KROS stock has decreased by 2.6% and is now trading at $15.4140.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) released its earnings results on Wednesday, August, 6th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.38. The firm's revenue was up 49002.7% on a year-over-year basis.

When did Keros Therapeutics IPO?

Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' top institutional investors include Geode Capital Management LLC (2.04%), Federated Hermes Inc. (1.61%), PDT Partners LLC (0.82%) and Canada Pension Plan Investment Board (0.78%). Insiders that own company stock include Adar1 Capital Management, Llc, Carl L Gordon, Carl L Gordon and Keith Regnante.
View institutional ownership trends.

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KROS
• CIK: 1664710
• Web: www.kerostx.com
• Phone: 617-314-6297
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Keros Therapeutics: $30.00
• High Price Target: $102.00
• Low Price Target: $15.00
• Potential Upside/Downside: +95.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.31
• Trailing P/E Ratio: 49.57
• Forward P/E Ratio: N/A
• P/E Growth: 1.92
• Net Income: -$187.35 million
• Net Margins: 8.06%
• Pretax Margin: 11.55%
• Return on Equity: 2.96%
• Return on Assets: 2.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.11
• Quick Ratio: 21.11

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 175.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.40 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 40,620,000
• Free Float: 32,248,000
• Market Cap: $622.50 million
• Optionable: Optionable
• Beta: 1.33